ELEVATE-TN clinical trial summary
A summary of the ELEVATE-TN trial, including 6 year follow up data: CALQUENCE with or without obinutuzumab vs. chlorambucil plus obinutuzumab for treatment-naïve CLL.
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
September 2025 I GB-69434